We need approval for Leronlimab for combo, off-label usage will quickly become normal and popular. CYDY is not allowed to advertise off-label drug use but HIV-1 population will quickly accept something better. Some companies do not go into additional trials for finance but already count on off-label. Leronlimab becomes the Gilead competition as soon as it is approved as a combo.